CHITOSE and FUJIFILM Biosciences announce strategic alliance for biopharmaceutical production
Chitose Laboratory Corp. and FUJIFILM Biosciences Inc. have formed a strategic alliance to advance biopharmaceutical manufacturing by combining CHO-MK cell line technology with GMP-manufactured culture media. The collaboration aims to enhance production efficiency and support the development of therapeutic solutions for the global pharmaceutical industry.
The partnership brings together CHITOSE’s expertise in cell line development using established CHO-MK cells with FUJIFILM Biosciences’ capabilities in culture media development and manufacturing. This integration of complementary technologies is designed to accelerate biopharmaceutical manufacturing processes whilst addressing current industry challenges in therapeutic production.
CHO-MK cell technology demonstrates enhanced productivity
CHITOSE’s proprietary CHO-MK cell line utilises a high-expression vector system that enables scalability for antibody and recombinant protein production. The technology has been developed to reduce manufacturing time and costs associated with biopharmaceutical development. When cultured in optimised AdaptPD CHO-MK Platform Medium A and AdaptPD CHO-MK Feed 1, the CHO-MK cells demonstrate growth characteristics that generate highly productive cells, resulting in higher titres and improved quality of biopharmaceutical products.
“Together, the combined expertise of CHITOSE and FUJIFILM Biosciences is set to create comprehensive solutions that not only enhance manufacturing efficiencies but also provide an integrated approach to tackling challenges in the global biopharma landscape,” said Takayuki Horiuchi, chief technology officer at Chitose Laboratory Corp.
GMP-manufactured media platform supports bioprocessing consistency
FUJIFILM Biosciences contributes its GMP-manufactured cell culture AdaptPD CHO-MK Platform Media to the alliance. The media platform has been designed to optimise CHO-MK cell growth and productivity across a range of biopharmaceutical applications. Drawing on decades of experience in life sciences, FUJIFILM Biosciences’ solutions are engineered to ensure consistency and reliability throughout bioprocessing stages.
The company’s expertise in culture media development complements CHITOSE’s cell line technology, creating an integrated approach to biopharmaceutical manu-facturing that addresses both upstream and downstream processing requirements.
Alliance targets therapeutic development and accessibility
The strategic collaboration aims to improve pharmaceutical production methods and support the development of new therapies for patients worldwide. By combining their respective technologies, both companies seek to help expand access to life-saving treatments through enhanced manufacturing efficiency.
“We’re excited about this strategic alliance as it underscores a shared vision of advancing therapeutic development by providing solutions designed to meet the growing demand for making biopharmaceuticals more accessible for treating conditions,” said Yutaka Yamaguchi, chairman and chief executive officer at FUJIFILM Biosciences. “FUJIFILM Biosciences forms alliances with like-minded companies like CHITOSE to drive meaningful progress and to create a lasting impact across life sciences.
